Business Context and Reporting Period
Company: SIM Acquisition Corp. I (SIMA)
Filing Type: Form 10-Q (Quarterly Report)
Reporting Period: Quarter ended June 30, 2025
Business Overview: SIM Acquisition Corp. I is a Cayman Islands exempted company formed as a Special Purpose Acquisition Company (SPAC). The Company consummated its Initial Public Offering (IPO) on July 11, 2024, raising $230 million. It has not yet commenced operations or selected a target business. The Company is focused on the healthcare industry and has until July 11, 2026, to consummate a Business Combination or face mandatory liquidation.
Key Financial Metrics
| Metric | As of/For Period Ended June 30, 2025 | As of/For Period Ended Dec 31, 2024 |
|---|---|---|
| Cash (Outside Trust) | $346,169 | $697,085 |
| Trust Account Balance | $240,266,117 | $235,322,812 |
| Total Assets | $240,822,286 | $236,327,097 |
| Net Income (3 Months) | $2,297,552 | N/A (Pre-IPO) |
| Net Income (6 Months) | $4,520,298 | N/A (Pre-IPO) |
| General & Administrative Expenses (6 Months) | $423,007 | N/A (Pre-IPO) |
| Deferred Underwriting Payable | $10,950,000 | $10,950,000 |
| Shares Outstanding (Class A) | 23,000,000 (Subject to Redemption) | 23,000,000 |
| Shares Outstanding (Class B) | 7,666,667 | 7,666,667 |
Material Changes vs. Prior Period
- Trust Account Growth: The Trust Account balance increased by approximately $4.94 million from December 31, 2024, to June 30, 2025, driven by interest income earned on U.S. Treasury securities held within the account.
- Operating Cash Flow: Net cash used in operating activities for the six months ended June 30, 2025, was $350,916, primarily due to general and administrative expenses offset by changes in working capital.
- Redemption Value Accretion: The carrying value of Class A ordinary shares subject to possible redemption increased to $240,166,117 (approx. $10.44 per share) from $235,222,812 (approx. $10.11 per share) due to accretion of interest income.
- Liquidity Position: Cash held outside the Trust Account decreased by approximately $350,916 during the six-month period, reflecting ongoing operational burn.
Outlook, Risks, and Management Commentary
- Going Concern Uncertainty: Management has determined that the mandatory liquidation deadline (July 11, 2026) raises substantial doubt about the Company's ability to continue as a going concern. The financial statements do not include adjustments that might be necessary if the Company is unable to continue.
- Liquidity Constraints: As of June 30, 2025, the Company's cash balance ($346,169) does not exceed its current budgeted operating requirements. Management concluded the Company may not have sufficient liquidity to meet obligations within one year without additional financing or a Business Combination.
- Extension and Liquidation: If a Business Combination is not consummated by July 11, 2026, the Company will cease operations, redeem 100% of public shares from the Trust Account, and liquidate. Warrants will expire worthless.
- Working Capital Loans: The Sponsor or affiliates may provide Working Capital Loans to fund transaction costs or working capital deficiencies. Up to $1.5 million of such loans may be convertible into warrants.
- Regulatory Environment: The Company is subject to new SEC rules for SPACs adopted in 2024, which may increase costs and time required to complete a Business Combination.
Investor Verification Checklist
- Liquidity Runway: Verify if the current cash balance of ~$346k is sufficient to fund operations until the July 2026 deadline or if immediate capital raises are required.
- Target Search Status: Confirm if the Company has identified a specific target in the healthcare sector or entered into any definitive agreements.
- Redemption Risk: Assess the likelihood of significant shareholder redemptions upon a potential Business Combination, which could impact the post-merger capital structure.
- Deferred Fees: Note the $10.95 million deferred underwriting fee payable only upon successful completion of a Business Combination.
- Going Concern Disclosure: Review the specific language regarding the "substantial doubt" on going concern status and any plans to extend the combination period.